Global Infectious Disease Drug Market: Rising Prevalence of Infectious Disease Accelerates the Demand of Infectious Disease Drug

Infectious Disease Drug Market

Infectious diseases are those which are usually caused by microorganisms such as viruses, bacteria, parasites, and fungi which usually live in or on our body. These diseases can be caused from person to person, insects, or animals. Persons who have probably developed a weakened immune system may have been susceptible to infection. Usually the symptoms of this condition depend upon the organism which causes the infection. Due to climate change, the prevalence of infectious diseases has increased. Some of the common infectious diseases are Lyme disease, jaundice, listeria, ebola, severe acute respiratory syndrome, west nile, among others. Today, there are various drugs available in the market so they can be cured easily. Few of the common drugs which are used are omadacycline, tecovirimat, tafenoquine, benzidazole, daclatasvir, among others.

Access Full Report at

Factors which are responsible for the growth of Infectious Disease Drug Market are:

  • Increases of cases of prevalence rate of infectious diseases worldwide: These days’ infectious diseases are increasing rapidly. Many infections are harmless and hardly visible, but others are serious and life-threatening. Some of the factor due to which these diseases transmit are bodily fluids, skin contact, touching infected person, and from airborne particles. It is said that the cause of an infection is the type of organism that has invaded the body
  • Rising awareness about treatment and technological advancement: Improvement in the healthcare industry and technological advancement and development in drug discovery is helping the people to get better treatment and drugs to cure different diseases. Many tests are available in the market which helps them to easily detect the infection and get early treatment so they can ignore the serious situations. Government is also taking different initiatives so they can help the people to get better treatment facilities

Some of the launches and acquisitions in the Infectious Disease Drug Market are as follow:

  • In October 2018, Bruker announced that they have acquired 80% stakes of Hain Lifescience GmbH. This acquisition will help the company to enhance their Bruker's microbiology and diagnostics business with a competitive portfolio of molecular diagnostics and a big technology portfolio. Hain is an established specialist in mycobacteria and the technology pipeline Bruker-Hain Diagnostics that will further improve TB testing with more differentiated diagnostic data
  • In November 2017, MELINTA THERAPEUTICS, INC. announced the acquisition of the infectious disease business from The Medicines Company. This business consists of three drugs; Vabomere; Orbactiv; and Minocin IV. This acquisition will help the company to enhance their market position and will also help them serve better services to their customers.

The global infectious disease drug market is segmented on the basis of source type as bacterial diseases, virusal diseases, fungal disease and parasitic disease; disease type as jaundice, leprosy, listeria, lyme disease, malaria, measles, molluscum contagiosum, molluscum contagiosum, norovirus, pyelonephritis, rabies, severe acute respiratory syndrome, sepsis, tetanus, west nile, zika, ebola disease and others; treatment type as medication, dietary supplements and surgery; mode of action type as antibacterial drugs, antiviral drugs, antifungal drugs, antiparasitic drugs; drug type (tafenoquine, omadacycline, tecovirimat, eravacycline, delafloxacin, plazomicin, benznidazole, secnidazole, daclatasvir, dalbavancin and others; route of administration as oral, topical and intravenous and end- users as hospitals, homecare, specialty clinics, others.

“According to Data Bridge Market Research, Global Infectious Disease Drug Market is set to witness substantial 5.5% in the forecast period of 2019- 2026”

Few of the major competitors currently working in the Infectious Disease market are F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (US), GlaxoSmithKline Plc (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc. (US), AbbVie Inc. (US), Vertex Pharmaceuticals Incorporated (US), ViiV Healthcare group of companies (UK), Sanofi S.A (France), Eli Lilly and Company (US) , Novartis AG (Switzerland), Mitsubishi Tanabe Pharma Corporation (Japan) and few among others.

Growing prevalence for infectious diseases and increasing demand for personalized medicines are the factor for the market growth. Government is also taking many initiatives and investing for the infectious disease diagnostics. Technological advancement and development in genomics and proteomics is another factor affecting the market positively. These are some of the factors which are creating new opportunities for this market.

Browse in Healthcare Related Reports@